Moreover, our study revealed that the expression levels of four genes (POSTN, CHI3L1, SAA1, and MMP9) were significantly elevated in glioma samples obtained from patients who experienced recurrence within one year after TMZ treatment, along with an increased risk score. The gene discussed is CHI3L1; the disease is glioma.